ABSTRACT VEGF, an endothelial-specific mitogen, is an important tumor angiogenesis growth factor. The major receptor for VEGF on endothelial cells is KDR. We hypothesized that an intrabody could bind newly synthesized KDR and block receptor transport to the cell surface, thereby inhibiting important VEGF effects. We expressed a single chain antibody (p3S5) to KDR with or without the endoplasmic reticulum (ER) retention signal (KDEL), using either a plasmid (p3S5-HAK) or a tet-off adenoviral system (Ad-HAK). Plasmid-mediated expression of the tethered intrabody significantly reduced KDR expression (from 82.5±12.5% to 27.9±13.6% of cells; P<0.01) and thymidine incorporation in successfully transfected cells. Ad-HAK infection resulted in intrabody expression in >90% of human umbilical vein endothelial cells (HUVECs), producing marked (80%) apoptosis at 48 h postinfection. The intrabody was essential for these effects, as confirmed by inhibiting its expression with doxycycline or by expressing irrelevant genes (lacZ, GFP). Cell death was dependent on KDR, because Ad-HAK infection of cell lines with minimal or no KDR had little effect on cell viability. Infected HUVECs were unable to form tubes on Engelbreth Holm-Swarm (EHS) tumor gel matrix. These results demonstrate the potential for development of an intrabody-based strategy to block angiogenesis and prevent tumor growth.
In this study, we have used an intrabody strategy to inhibit VEGF receptor-2 (KDR) expression on human umbilical vein endothelial cells (HUVECs). The single chain antibody (p3S5) was expressed using plasmid-mediated transfection and adenoviral infection. The expression of the intrabody resulted in decreased KDR cell surface expression, decreased proliferation in response to VEGF, the induction of apoptosis, and the inhibition of tube formation. Our study suggests that an intrabody to KDR should be considered for development as a method for inhibiting tumor angiogenesis.
MATERIAL AND METHODS

Cell culture
HUVECs were obtained from Clonetics (San Diego, CA) and grown in endothelial cell growth medium (EGM-2) (Clonetics) in a humidified incubator under 5% CO 2 at 37°C. Passage 2-5 of HUVECs were used in experiments.
Construction of expression vectors (p3S5-HA and p3S5-HAK)
A plasmid containing single chain antibody scFv p3S5 was obtained from Imclone Systems (New York, NY). The single chain antibody binds to an epitope that is located on KDR extracellular Ig domain 1. VEGF binding to KDR is not blocked by p355, nor does it have any effect on VEGF-induced receptor activation, including KDR phosphorlyation or induction of DNA synthesis (27) . The scFv p3S5 cDNA was amplified by two polymerase chain reactions (PCRs) with the sense primers (P1: 5′-GCTCCCAGATGGGTCCTGTCCC AGGTGAAACTGCAG  GAGTCA-3′ and P2: 5′-TTTGAATTCATGGAACAT CTGTGGTTCTTCCTTCT CCTGGTGG   CAGCTCCCAGATG   GGTCC  TGT  CC-3′),  and  antisense  primer  (5′-TTCTAGAGGATCCTTACGCCCGTTT TATTTCCAA-3′ ). An HA tag sequence (YPYDVPDYA) was linked to the scFv gene by a PCR reaction with the sense primer (P1 and P2) and antisense primer (P3: 5′-TTTCTAGAGGATCCTTAAGC ATAA TCTGGAACATCATATGGATACGCCCGTTTTATTTCC AA-3′). The scFv p3S5 gene tagged with HA was then linked with an endoplasmic reticulum (ER) retention signal (SEKDEL) by a PCR reaction with sense primer (P2) and antisense primer (P4: 5′-TTTTCTAGAGGAT CCTTACAG CTCGTCCTTCTCGCTAG CATAATCTGGAACATCATA-3′).
These DNA fragments were digested with BamHI and EcoRI and were cloned into the expression vector pIRES2-EGFP (Clontech, Palo Alto, CA). All of the constructs were identified by restriction enzyme digestion and confirmed by DNA sequencing (Sequencing Core Facility, Wake Forest University School of Medicine, Winston-Salem, NC).
Construction of Ad-HA or Ad-HAK recombinant virus and cell infection
The cDNA for p3S5-HA(K) was cloned into the pTRE-shuttle vector (Clontech), using SacII and BamHI restriction sites located in the MCS region of this vector (sense primer, TTTCCGCGGGAATTCATGGAACATCTGTGG, and antisense primer, P3 for Ad-HA and P4 for Ad-HAK). This plasmid construct was confirmed by sequencing both strands (Sequencing Core Facility). Recombinant adenoviral DNA containing p3S5-HA(K) cDNA was then produced by ligating the p3S5-HA(K) expression cassette to Adeno-X viral DNA by using I-Ceu I and PISce I restriction sites. These recombinant adenoviral DNA constructs were confirmed by PCR and restriction enzyme digestion methods. Recombinant adenovirus was propagated and purified by first transfecting low passage HEK293 cells with Pac I-digested recombinant adenoviral DNA, using standard lipofectamine transfection techniques, and then harvesting and amplifying recombinant viral particles in HEK293 cells (virus titer Ad-HA: 8×10 6 pfu/ml; Ad-HAK: 5×10 6 pfu/ml).
The recombinant adenovirus has a tet-response element located upstream of the minimal immediate early promoter of cytomegalovirus (P mincmv ). When cotransfected with the adeno-X tet-off virus, which produces the tetracycline-controlled transactivator (tTA), the recombinant adenovirus Ad-HA or Ad-HAK can be expressed in the absence of tetracycline or doxycycline but is inhibited in the presence of tetracycline or doxycycline. HUVECs were infected at a multiplicity of infection (MOI) of ~10 pfu per cell.
Other adenoviruses
Adeno-GFP virus was a gift from Dr. David A. Ornelles (Department of Microbiology and Immunology, Wake Forest University School of Medicine) (virus titer Ad-GFP: 4.2×10 8 pfu/ml) (28) . Adeno-X tet-off and Adeno-LacZ viruses were purchased from Clontech and amplified in HEK293 cells (virus titer Ad-LacZ: 3×10 7 pfu/ml; tet-off virus: 4 × 10 7 pfu/ml). Adeno-X tet-off virus was used in each experiment to co-infect cells, along with recombinant or LacZ adenovirus infection. Ad-PEPCK-1D1 (1.4×10 11 pfu/ml) was obtained from Dr. Lawrence Chan (Baylor College of Medicine, Houston, TX). This adenovirus expresses the scFv 1D1 from the PEPCK promoter and contains the SEKDEL ER retention sequence. All adenoviral infections were performed at 10 pfu per cell.
Plasmid transfection
Lipofectamine reagent (Gibco-BRL, Gaithersburg, MD) was used in plasmid transfections of HUVECs. The "Gibco transient or stable transfection of adherent cells protocol" was followed. In brief, in a 35-mm tissue culture plate, 3 × 10 5 HUVECs were seeded and incubated overnight at 37°C in 5% CO 2 . Plasmid DNA (2 µg) and lipofectamine reagent (7 µl) were diluted into 100 µl OPTI-MEM I Reduced Serum Medium (Gibco-BRL), respectively. The two solutions were mixed and incubated at room temperature for 30 min. Following incubation, 0.8 ml OPTI-MEM I Reduced Serum Medium was added to the mixture. The diluted solution was added to the 35-mm HUVEC plate and incubated for 5 h at 37°C in 5% CO 2 . EGM-2 complete medium (0.8 ml) was added at the last hour of incubation. Following incubation, fresh EGM-2 medium was added to the HUVECs, and the cells were incubated at 37°C in 5% CO 2 .
Immunofluorescence assay
In a 35-mm culture dish, 1 × 10 5 cells (plasmid transfected or adenovirus infected) were seeded and incubated overnight. The next day, the cells were fixed with 3.7% formaldehyde (Sigma, St. Louis; MO) in PBS and incubated at room temperature for 30 min. After cells were washed in PBS, we added Triton X-100 (0.2% in PBS) and incubated the cells at room temperature for 10 min. The cells were blocked with PBA (PBS+1% BSA) before incubating with the first antibody (mouse anti-HA monoclonal antibody [Babco, Berkeley, CA]) followed by the second antibody (rhodamine-conjugated/anti-mouse lgG [Jackson ImmunoResearch Laboratories, West Grove, PA]), respectively. The cells were washed three times with PBS between each step. Then the cells were fixed with 3.7% formaldehyde before they were observed using a fluorescence microscope (Axioplan 2; Zeiss, Oberkochen, Germany).
For immunostaining of caspase-3 and DAPI staining, the steps were followed as for Ad-HAKinfected HUVECs. The first antibody reacts selectively with activated caspase-3 (rabbit antihuman caspase-3 antibody, 1:50 dilution; Cell Signaling Technology, Beverly, MA). The second antibody was rhodamine-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch Laboratories) After washing in PBS and fixing again with 3.7% formaldehyde at room temperature for 10 min, DAPI (Sigma) in methanol was added for 5 min and plates were washed with methanol and PBS before being observed with a fluorescence microscope.
Western blot
Forty-eight hours after plasmid transfection or adenovirus infection, the culture medium was collected and HUVECs were lysed with modified radioimmunoprecipitation (RIPA) buffer (Upstate Biotechnology, Waltham, MA). The culture medium was concentrated by centripreps (Amicon, Bedford, MA). Samples of the denatured cell lysate and culture medium were loaded on a 15% SDS-PAGE gel. Equal amounts of protein were loaded into each well. The gel was transferred onto a nitrocellulose membrane (Bio-Rad, Hercules, CA). The membrane was blocked with TBS-Tween (0.1%) plus 5% dry milk and blotted with mouse monoclonal anti-HA antibody (Babco) as first antibody, and horseradish peroxidase-conjugated anti-mouse IgG (Amersham, Piscataway, NJ) as second antibody. The peroxidase reaction was visualized using chemiluminescence (Amersham), and the exposed film was developed.
Cell flow cytometry assay and cell sorting
Twenty-four or 48 h after plasmid transfection or adenovirus infection, HUVECs were collected and divided into two groups. One group was incubated with mouse anti-KDR monoclonal antibody (1:50 dilution) (Sigma) or anti-α v β 3 (MAB 1976 
Thymidine incorporation assay
The sorted HUVECs in normal endothelial cell growth medium were plated onto a 96-well plate at a density of 5 × 10 3 cells/well in triplicate for 24 h. The next day, the medium was changed to endothelial cell basal medium containing 0.5% fetal bovine serum and 0.1% bovine serum albumin (starvation medium) overnight. The starved cells were incubated with VEGF 165 (15 ng/ml; Calbiochem, San Diego, CA) or bFGF (10 ng/ml; R&D Systems, Minneapolis, MN) for 30 h. [ 3 H] thymidine (1µ Ci) was added to each well during the last 6 h of incubation. [ 3 H] thymidine-labeled DNA was harvested onto Whatman (Clifton, NJ) GF/B paper and free thymidine was washed away from the precipitate using 10% cold TCA. The filter paper was then assayed for [ 3 H] using a Beckman liquid scintillation counter.
3-[4, 5-Dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide (MTT) assay
In a 96-well plate, 1 × 10 4 cells (HUVECs, HASMC, BT474, or MCF-7) were seeded in complete medium in each well and incubated overnight. The next day, the cells were infected with recombinant adenovirus and tet-off virus and incubated for 4 h at 37°C in 5% CO 2 before doxycycline was added to some wells. The cells were further incubated for 12-72 h in complete medium before 10 µl of MTT (Sigma) solution (5 mg/ml) was added to each well and incubated for another 3 h. Isopropanol with 0.04 N HCl was added into each well to lyse the cells and solubilize the formazan product before the plate was read at dual wavelengths in a V max ELISA plate reader (OD 560 nm to OD 650 nm).
Time-lapse video microscopy
HUVECs (6×10 5 ) were seeded into a T-25 tissue culture flask (Corning, Corning, NY) and incubated overnight before Ad-HAK was added in the presence or absence of doxycycline. The T-25 flask was placed in the dedicated incubator of an inverted phase contrast video microscope (Axiovert, Zeiss) for observation for 48 h. For time-course studies, a cell was considered to have entered apoptosis at the first appearance of membrane blebs, one of the earliest morphological events of apoptosis. Each cell in the field of observation was followed, and the time that the cell underwent apoptosis was recorded.
Tube formation assay
This assay was performed following the instructions from the in vitro angiogenesis assay kit (Chemicon International). In brief, ECMatrix solution and diluent buffer were thawed on ice before 100 µl of 10× diluent buffer was added to 900 µl of ECMatrix solution and then mixed in a sterile microfuge tube and kept on ice. The mixture (50 µl/well) was transferred to a 96-well tissue culture plate and incubated at 37°C for 1 h to solidify the matrix. The HUVECs that had been treated with recombinant or control adenovirus in the presence or absence of doxycycline for 24 h were harvested. HUVECs were seeded (7500 cells per well) onto the surface of the polymerized ECMatrix and incubated at 37C° overnight in a CO 2 incubator before tube formation was inspected under an inverted microscope (Axiovert, Zeiss).
RESULTS
Plasmid-mediated expression and intracellular localization of modified p3S5-intrabody
The p3S5 single chain antibody cDNA with or without an ER retention sequence (KDEL) was cloned into the Bam HI and EcoRI restriction sites of the pIRES2-EGFP vector (Fig. 1 ). An influenza hemagglutinin (HA) epitope was linked to facilitate protein detection (Fig. 1) . The expression of EGFP could be detected in transfected cells by using fluorescence microscopy ( Fig. 2) . To determine the localization of the modified p3S5, immunofluorescent staining was performed using an antibody to the HA epitope. Figure 2 demonstrates that a cytoplasmic ER staining pattern was observed in the p3S5-HAK-transfected HUVECs. Cells that did not express EGFP had no evidence of fluorescence with anti-HA (Fig. 2) , demonstrating specificity of the antibody and the lack of secretion of the intrabody with rebinding to neighboring cells. Cells transfected with the vector expressed EGFP but did not exhibit fluorescence with anti-HA (Fig.  2, arrows) .
To examine the expression of modified p3S5-intrabody further, HUVECs were transfected with either pIRES2-EGFP control, p3S5-HA, or p3S5-HAK, and 48 h later, the cell lysates and concentrated culture medium were immunoblotted with an anti-HA antibody. A 30-kDa protein band corresponding to the intrabody was found exclusively in the cell lysate (Fig. 3, lane 3) and not in the culture medium of p3S5-HAK-transfected cells (Fig. 3) . As expected, no immunoreactivity was found in control vector-transfected cell lysates (Fig. 3 ) or culture medium (Fig. 3 ). Cells transfected with p3S5-HA showed significant secretion of the antibody into the culture medium (Fig. 3) .
Effects of the modified p3S5-intrabody on KDR expression of transfected HUVECs
To determine the effect of the modified p3S5-intrabody on KDR expression, we transfected HUVECs with pIRES2-EGFP (control vector), p3S5-HA, or p3S5-HAK, and 48 h later, we examined the cell surface expression of KDR by using flow cytometry and performing two-color analysis (Fig. 4) . Whereas only 17.5 ± 7.2% of cells transfected with pIRES2-EGFP failed to express KDR, 72.1 ± 7.8% of cells transfected with p3S5-HAK were KDR negative (P<0.01; Fig. 4) . Transfection with the p3S5-HA vector without the KDEL tag was not effective in suppressing KDR expression, with 21.4 ± 6.2% of the EGFP-expressing cells having no detectable KDR (P>0.1).
We found that ≤7% of cells expressed HA antigen after infection with Ad-HA or Ad-HAK. Furthermore, there was minimal (≤15%) inhibition of anti-KDR by preincubating HUVECs with intrabody (data not shown). Therefore, we do not believe that a "masking" effect of the intrabody can explain the lower levels of surface KDR.
Inhibition of HUVEC proliferation by the modified p3S5-intrabody
To examine the effects of the modified p3S5-intrabody on HUVEC proliferation, HUVECs were transfected with p3S5-HAK or p3S5-HA. After 48 h in culture, they were sorted based on EGFP expression into transfected (+) and nontransfected (-) groups, then left in serum-free medium (control) or treated with VEGF 165 at 15 ng/ml or bFGF at 10 ng/ml for 30 h. A [ 3 H] thymidine incorporation assay was performed on these cells. The proliferation rate of the cells that had been transfected with p3S5-HAK was significantly lower than that of cells that were not transfected (P<0.05) in response to VEGF (Fig. 5) . However, p3S5-HAK transfection did not inhibit the proliferation of HUVECs in response to bFGF. There was no significant difference between p3S5-HA-transfected and nontransfected cells (P>0.1; data not shown).
Ad-HAK mediated expression of intrabody
Because the maximum transfection efficiency achieved with the plasmids was 13.3%, an adenovirus-based strategy for expressing the intrabody was developed (Fig. 1) . As shown in Figure 3 , immunoblotting with anti-HA resulted in the detection of bands of ∼30 kDa in cell lysates of Ad-HA-and Ad-HAK-infected cells but in the culture medium only with Ad-HA. To determine the expression and intracellular localization of the recombinant adenovirus, an immunofluorescent assay was performed with Ad-LacZ-, Ad-HA-, or Ad-HAK-infected HUVECs, 48 h postinfection (Fig. 6 ). Anti-HA was used as the first antibody and rhodamineconjugated anti-mouse IgG as the second antibody. Cytoplasmic ER patterns were exhibited in Ad-HA-or Ad-HAK-infected HUVECs but not with Ad-LacZ infections (Fig. 6) . Expression of the intrabody was inhibited in the presence of 100 ng/ml doxycycline. Flow cytometry of Ad-HAK-infected HUVECs at 24 h demonstrated markedly reduced KDR expression in Dox (-) HUVECs (from 63.0% of cells to 7.0%), but not α v β 3 expression (98.7% to 99.3%; data not shown).
Doxycycline concentration curve
The effect of doxycycline concentration on reversal of cell death induced by Ad-HAK infection was studied. As shown in Figure 7 , concentrations of >10 ng/ml completely reversed the effect of Ad-HAK on cell survival. There was a dose-dependent inhibition of intrabody expression with complete suppression at 100 ng/ml (Fig. 7, inset) .
Ad-HAK-mediated intrabody expression promotes apoptosis in HUVECs
HUVECs infected with Ad-HAK had progressive cell death of 70-80% at 48-72 h postinfection (Fig. 8) , which was inhibited by doxycycline. In contrast, HUVECs infected with Ad-HA, AdLacZ, and Ad-PEPCK-1D1 grew at 80-100% of control (uninfected) cells.
Time-lapse video microscopy of Ad-HAK-infected HUVECs in the presence or absence of doxycycline (100 ng/ml) was performed. The percent of apoptotic cells per high power field was quantified at hourly intervals. Figure 9A shows frames from the time-lapse video microscopic analysis of apoptosis of Ad-HAK-infected HUVEC at 24 and 48 h. The apoptosis was inhibited by doxycycline (Fig. 9A, lower panel) . Cells infected with Ad-HAK had evidence of caspase-3 activation and nuclear segmentation (demonstrated by DAPI staining), which was inhibited by doxycycline (Fig. 9C) . Noninfected cells also lacked evidence of caspsase-3 activation, whereas cells that were serum-starved for 48 h demonstrated apoptosis and caspase-3 activation (data not shown). As shown in Figure 9B , Ad-HAK induced cells to undergo progressive apoptosis over the 48-h time course, which was completely prevented by doxycycline (data not shown).
Cell specificity of apoptosis induction with Ad-HAK
A variety of cells were infected with Ad-HAK in order to test the cell specificity of the intrabody effect. As before, HUVECs were killed by Ad-HAK, an effect reversed by doxycycline (Fig. 10) . In contrast, BT474, MCF-7, and SMCs were relatively unaffected by Ad-HAK infection (Fig.  10) , even though the infection success rate was ≥90% and all cells expressed intrabody, as detected by immunoflourenscence, using anti-HA (data not shown). These cells were found to express little, if any, cell surface KDR by flow cytometric analysis (data not shown).
Ad-HAK-mediated intrabody expression inhibits tube formation
Ad-HAK-infected HUVECs showed a gross defect in the ability to form tubes, using the EHS gel assay. In some cases, it appeared that cells aligned into tubes but then underwent apoptosis. The defect in tube formation was reversed in the presence of doxycycline (100 ng/ml). In contrast, infection with Ad-LacZ, Ad-GFP, or both viruses had minimal or no effect on tube formation (Fig. 11) .
DISCUSSION
In this paper, we show that an intrabody strategy using a single chain antibody with a C-terminal ER retention signal (KDEL) is highly effective in reducing endothelial cell surface expression of VEGFR-2 (KDR). With the plasmid-based strategy, we demonstrated that >70% of the transfected endothelial cells had no detectable surface KDR and had a greatly reduced mitogenic response to VEGF 165 . With the adenoviral system, which resulted in much higher expression efficiency, we found that the intrabody induced apoptosis and inhibited tube formation. Intrabody expression was essential for these effects as confirmed by control experiments using doxycycline and adenoviruses expressing irrelevant gene products. Furthermore, these effects were KDR dependent, as cells that do not express KDR were not sensitive to the KDR intrabody.
The intrabody strategy depends on a receptor-mediated system for retention of certain proteins within the ER. After being cotranslationally transported to the lumen of the ER, some proteins are retained within the ER rather than being secreted. Examples include BiP (29) and protein disulfide isomerase (30) , which assist in protein folding and disulfide bond formation, respectively. Retained proteins contain specific signals (KDEL or HDEL) at their C terminus (31, 32 ) that bind to the ER retention receptors ERD2.1 and ER2.2, resulting in their retrieval from the cis-Golgi compartments (33) (34) (35) . The KDEL retention sequence was used in our experiments to tether the single chain antibody within the ER.
VEGF has been demonstrated to be an important growth factor in promoting endothelial cell survival by inhibiting apoptosis. Alon et al. found that VEGF acts in vivo as an endothelial cell survival factor by showing that hyperoxia-induced down-regulation of VEGF expression in the neonatal rat retina leads to the regression of retinal capillaries via selective apoptosis of endothelial cells. This effect could be prevented by intraocular injection of VEGF (36) . Moreover, additional studies demonstrated that inhibition of VEGF leads to apoptosis of endothelial cells and vessel regression in several models of tumor angiogenesis (37) (38) (39) (40) . Recent studies have provided more insight into the antiapoptotic signaling that is mediated by VEGF. Up-regulation of antiapoptotic proteins, such as Bcl-2, A1, XIAP, and survivin, has been demonstrated by VEGF signaling through KDR (41) (42) (43) . Furthermore, activation of the antiapoptotic protein kinase phosphotidylinositol 3 kinase (PI3K/Akt) is involved in VEGFpromoted endothelial cell survival (44, 45) .
The KDR receptor is an attractive antiangiogenesis target, because it is expressed almost exclusively on activated endothelial cells, in contrast to Flt-1, which is expressed on both proliferating and quiescent endothelial cells (46) (47) (48) (49) (50) . A variety of strategies have been used to target KDR or its ligand VEGF. A monoclonal antibody against VEGF was used in nude mice with xenografted human tumors, demonstrating that blocking VEGF signaling inhibited tumor growth in vivo (51) . Soluble VEGF receptors can significantly inhibit tumor cell implantation and growth by directly neutralizing VEGF or by forming nonproductive heterodimers with cell surface receptors (52) . Anti-sense VEGF mRNA expressing constructs (53, 54) , VEGF-toxin conjugates (54) , and antagonistic VEGF mutants (56) have also been effective in animal models. RhuMAB VEGF, a humanized anti-VEGF antibody, is in clinical trial in cancer patients (57) . An alternative approach to targeting VEGF-induced angiogenesis is to block VEGF receptor functions by using antibodies, ribozymes (58) , or other inhibitor strategies. Animal studies using rat monoclonal antibody DC101, which is directed against the mouse Flk-1, significantly reduced xenografted tumor growth due to inhibition of tumor angiogenesis (59, 60) . KDR single chain antibody c-p1C11 and tyrosine kinase inhibitors are in clinical trials (61, 62) .
The intrabody strategy has several potential advantages over these previous approaches. By acting intracellularly, the intrabody can evade immune responses that can be elicited by extracellular antibodies, thereby avoiding the formation of neutralizing antibodies. Even though we demonstrated that the intrabody resulted in apoptosis of endothelial cells, it is likely that no intact intrabody would be released, because the intrabody-receptor complex undergoes extensive proteolysis in the cell (63.66 ). An extracellular antibody would be ineffective against receptors that are already ligated with VEGF, a known stimulus for inducing KDR expression (67) . Thus, even a small level of VEGF-KDR interaction that escapes the inhibition by an extracellular antibody could induce angiogenic responses. In contrast, the intrabody would be effective in trapping newly synthesized KDR occurring in response to VEGF stimulation. This strategy could be uniquely suited to inhibit the "internal autocrine loop" that has been demonstrated in certain hematopoietic malignancies (68) . In this case, newly synthesized VEGF is able to bind to and activate KDR within the ER of the cell, a site that is not accessible to conventional strategies such as extracellular antibodies (68) .
The intrabody-KDEL construct was designed to exploit the ER receptor-mediated retention system, binding to both KDR and the retention receptors, thereby preventing the transport of the KDR-intrabody complex to the cell surface. Only a small percentage (27.9%) of receptors were able to elude this trapping mechanism. Note that p3S5-HA transfection or Ad-HA infection were not effective in reducing KDR expression, consistent with prior observations that tethering with KDEL greatly enhances receptor trapping within the ER (69) . Thus, the expression and receptor binding of intrabody alone are not able to significantly affect the trafficking of the KDR to the cell membrane. We saw no evidence for a transcellular mechanism of action, as has been previously reported for the intrakine SDF-1α (70) . This mechanism can occur when saturation of the ER retention receptors leads to secretion of KDEL-tagged proteins (71, 72) . However, in our study, there was no evidence that any secreted antibody rebound to neighboring cells, and no intrabody was detected in the culture medium of p3S5-HAK-transfected or Ad-HAK-infected cells. Furthermore, the EGFP-negative HUVECs derived from the population that was transfected with the p3S5-HAK intrabody vector had equal [ 3 H]-thymidine incorporation compared with those transfected with the vector. Thus, the inhibition of receptor expression probably occurred by trapping of the KDR within the ER by the KDEL-tagged intrabody.
In summary, we have shown that a tethered intrabody to KDR decreases cell surface expression of the receptor, resulting in endothelial apoptosis. HUVECs expressing the intrabody are unable to form tubes, demonstrating an antiangiogenic effect. The expression of an intrabody to KDR, especially using the adenoviral strategy, appears to be a promising method for inhibiting tumor angiogenesis. p3S5-HA contains the influenza virus hemogglutinin antigen domain HA epitope; p3S5-HAK contains both HA epitope and KDEL sequences. The recombinant adenoviruses were constructed as described in the text, using the tet-off system (Clontech). Ad-HA contains the intrabody and HA tag, whereas Ad-HAK also contains the KDEL sequence. At 48 h postinfection, cells were stained using anti-HA antibody, followed by rhodamine-conjugated anti-mouse IgG, and were analyzed by immunofluorescence microscopy. Ad-HA-and Ad-HAK-infected cells display reactivity with anti-HA in a pattern consistent with ER expression. The intrabody expression was inhibited by doxycycline (100 ng/ml; lower panels). Intrabody was not detected in Ad-LacZ-infected HUVEC. Ad-HAK in the presence of doxycycline at concentrations of 0, 0.1, 1.0, 10, and 100 ng/ml (logarithmic scale). At 48 h postinfection, the MTT proliferation assay was performed and the viable cell number was expressed as a percent of uninfected cells. In the absence of doxycycline, 7.8 ± 1.3% of the uninfected cells remained viable. Assays at each concentration of doxycycline were performed in replicates of four. Error bars represent ±1SE . Concentrations of doxycycline >10 ng/ml completely reversed the cell killing effect of Ad-HAK on HUVEC. Inset: Immunoblot of HUVEC cell lysates prepared from parallel experiments, using doxycycline concentrations of 0.1, 1, 10, and 100 ng/ml. The intrabody expression was totally inhibited at 100 ng/ml. 
